Abstract 5667
Background
DS-8201a is a novel antibody-drug conjugate comprised of a humanized HER2 antibody attached by a cleavable peptide-based linker to a topoisomerase I inhibitor; characterized by a high drug-to-antibody ratio of about 8. In an ongoing phase 1 trial, DS-8201a showed high and durable responses across multiple tumors, with a confirmed objective response rate (ORR) of 61.4% in previously T-DM1-treated HER2-positive (IHC 3+ or IHC2+ and ISH+) breast cancer (BC) and 31.6% in HER2 low-expressing (IHC 2+/1+ and ISH–) BC (Oct 2017 cutoff; Modi et al, SABCS 2017). Nivolumab, an anti-PD-1 antibody, is FDA-approved for metastatic urothelial carcinoma (UC) after platinum failure. A xenograft model of HER2-expressing cancer showed significantly increased survival with the combination of DS-8201a with an anti-PD-1 antibody vs either treatment alone (Iwata et al, ASCO 2017).
Trial design
This phase 1b, multicenter, open-label study will assess the combination of DS-8201a with nivolumab in previously chemotherapy-treated HER2-expressing advanced BC or UC. Previous treatment with anti-PD-1/PD-L1 therapy is an exclusion criterion. A dose escalation (part 1) will identify the recommended dose for expansion (RDE), and dose expansion (part 2) will evaluate efficacy and safety/tolerability of the DS-8201a RDE combination with nivolumab (360 mg IV; q3wk). Part 1 is a 3 + 3+3 design with 3 dose cohorts of DS-8201a (3.2, 5.4, and 6.4 mg/kg q3wk); enrollment will start at 3.2 mg/kg. Following RDE determination, enrollment in part 2 will open (Table); estimated total enrollment is 99–117. ORR is the primary efficacy endpoint; secondary endpoints include overall survival, disease control rate, duration of response, progression-free survival, time to response based on central review, and safety/tolerability. The study is open for enrollment as of May 2018.Table: 370TiP
| Part 2 Cohorts | |||
|---|---|---|---|
| Cohort | Cancer Type | HER2 Status | Approximate Enrollment |
| 1 | BC | HER2-positive (IHC 3+ or ISH+) | 30 |
| 2 | BC | HER2 low-expressing (IHC 2+/1+ and ISH–) | 15 |
| 3 | UC | HER2 high-expressing (IHC 3+/2+) | 30 |
| 4 | UC | HER2 low-expressing (IHC 1+) | 15 |
Clinical trial identification
NCT03523572.
Legal entity responsible for the study
Daiichi Sankyo, Inc.
Funding
Daiichi Sankyo, Inc.
Editorial Acknowledgement
Medical writing and editorial support was provided by Stefan Kolata, PhD of AlphaBioCom, LLC (King of Prussia, PA).
Disclosure
S.A. Hurvitz: Grants: Amgen, Bayer, BI Pharma, Genentech, GSK, Lilly, Novartis, Pfizer, Roche, PUMA, Merrimack, Medivation, Dignitana, OBI Pharma, Biomarin, Cacadian, Lilly, Novartis, OBI Pharma, Bayer. M.D. Galsky: Consultancy fees: Genetech, Merck, Novartis, Astellas, AstraZeneca, and BMS; Stock/stock options: Dual Therapeutics. J. Shahidi, G. Zhang, S. Raza: Full time employee: Daiichi Sankyo, Inc. A. Necchi: Personal fees: Roche, Janssen; Grants and personal fees: Merck, AstraZeneca.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract